Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
From available case reports, compounding pharmacy data, and practitioner experience, the following have been observed: BPC-157 Reported Side Effects Nausea and gastrointestinal discomfort (especially with oral administration) Dizziness or light-headedness Flushing or warmth at injection sites Headache Fatigue or somnolence in some users TB-500 Reported Side Effects Injection site reactions (redness, mild pain, swelling) Transient fatigue or lethargy following administration Headache Possible flu-like symptoms in a minority of users Critical Risk Note: Because neither peptide has undergone full clinical trial evaluation in humans, the complete adverse event profile is unknown
A compound that is clean enough for a binding assay is not automatically clean enough for a quantitative cell-based readout where a co-eluting impurity could carry activity of its own
Is BPC157 a risk
OL Research products are supplied in compliance with UK regulations governing research compounds.
BPC 157 as a research protocol for Retinal Ischemia Induced by Retrobulbar Application [PMID: 34177567] Laboratory literature summary: BPC 157 as a research protocol for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats
